Enlimomab

L-Histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-glutaminyl-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-lysyl-L-arginyl-L-tyrosyl-L-lysyl-L-glutaminyl-L-arginyl-L-valyl-L-lysyl-L-asparaginyl-L-lysine (ACI)

Immunoglobulin G1, anti-(human plasma kallikrein) (human monoclonal DX-2930 heavy chain), disulfide with human monoclonal DX-2930 light chain, dimer (ACI)

Sorbitan monododecanoate (ACI)

Rifalazil

MEDI 575

Ligelizumab

Radretumab

Immunoglobulin G4, anti-(human NKG2A/CD94 receptor) (human-mouse monoclonal humZ270 heavy chain), disulfide with human-mouse monoclonal humZ270 light chain, dimer (ACI)

Glembatumumab vedotin

Secukinumab

Blosozumab

Oxelumab

Dalotuzumab

Enavatuzumab

Samalizumab

Tabalumab

Itolizumab

Fresolimumab

Cixutumumab